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ABSTRACT
Introduction: Orbital decompression is the
indicated procedure for addressing
exophthalmos and compressive optic
neuropathy in thyroid eye disease. There are
an abundance of techniques for removal of
orbital bone, fat, or a combination published in
the scientific literature. The relative efficacy and
complications of these interventions in relation
to the specific indications remain as yet
undocumented. We performed a systematic
review of the current published evidence for
the effectiveness of orbital decompression,
possible complications, and impact on quality
of life.
Methods: We searched the current databases
for medical literature and controlled trials,
oculoplastic textbooks, and conference
proceedings to identify relevant data up to
February 2015. We included randomized
controlled trials (RCTs) comparing two or
more interventions for orbital decompression.
Results: We identified only two eligible RCTs
for inclusion in the review. As a result of the
significant variability between studies on
decompression, i.e., methodology and
outcome measures, we did not perform a
meta-analysis. One study suggests that the
transantral approach and endonasal technique
had similar effects in reducing exophthalmos
but the latter is safer. The second study provides
evidence that intravenous steroids may be
superior to primary surgical decompression in
the management of compressive optic
neuropathy requiring less secondary surgical
procedures.
Conclusion: Most of the published literature on
orbital decompression consists of retrospective,
uncontrolled trials. There is evidence from
those studies that removal of the medial and
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lateral wall (balanced) and the deep lateral wall
decompression, with or without fat removal,
may be the most effective surgical methods with
only few complications. There is a clear unmet
need for controlled trials evaluating the
different techniques for orbital decompression.
Ideally, future studies should address the
effectiveness, possible complications, quality
of life, and cost of each intervention.
Keywords: Decompression; DON;
Exophthalmos; Graves’; GO; Orbit;
Orbitopathy; Strabismus; TED; Thyroid
INTRODUCTION
Definition and Epidemiology
Graves’ orbitopathy (GO) or thyroid eye disease
(TED) is a disabling ocular presentation of
Graves’ disease (GD), causing cosmetic
changes and functional alterations. TED will
present in almost 50% of GD cases, whereas
approximately 5% of patients will develop
severe disease with dysthyroid compressive
optic neuropathy (DON) [1]. Recent
epidemiological studies show that GD has an
incidence of 210 per million per year in Sweden,
presenting more frequently in the fifth decade
of life. It more frequently affects women than
men, with a female to male ratio of 4:1. TED It is
an autoimmune disorder with an incidence of
42 per million per year [2]. The orbit is affected
due to expression of organ-specific
autoantibodies against the thyroid stimulating
receptor (TSH receptor) which presents both in
thyroid and periocular tissues [3].
Moderate-to-severe and very severe GO will
develop in 5–6% of GD cases, whereas mild
GO resolves spontaneously in most cases [4, 5].
Clinical presentation involves inflammation of
the orbital and periocular tissues, edema of the
extraocular muscles, and fat proliferation,
which increase the orbital volume, resulting in
exophthalmos and eyelid retraction. Restrictive
ocular myopathy due to muscle enlargement
and fibrosis result in diplopia. Eyelids,
conjunctiva, and caruncle most frequently
develop erythema and swelling due to
inflammation [6].
TED manifests initially with an active
inflammatory stage followed by a burnt out
fibrotic phase. Management of the active
disease is based on euthyroidism,
anti-inflammatory and immunosuppressive
agents, or retrobulbar radiotherapy guided by
the disease activity and severity scores [7].
However, functional and esthetic recovery in
the fibrotic stage may be incomplete, and
residual tissue scarring combined with
permanent periocular changes result in
persistent exophthalmos, diplopia, and lid
retraction, which require multiple
rehabilitative surgical interventions [8, 9].
Finally, the disease significantly diminishes
the quality of life [10].
Intervention
Orbital decompression is the indicated
intervention to restore optic nerve function in
cases with DON, to correct or prevent exposure
keratopathy due to lagophthalmos, and to
rehabilitate patients with disfiguring
exophthalmos. Surgery is performed by
removing orbital bone, fat, or both and has
only been applied for cosmetic rehabilitation in
the 1990s [11–13]. It aims for the removal of
medial, lateral, and inferior bony walls; this
expands the orbital space into the paranasal
sinuses and therefore increases the total
volume. The literature suggests that three-wall
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decompression is indicated in cases with high
degrees of proptosis, whereas two-wall
decompression is more appropriate for cases
with less exophthalmos [14–18]. Removal of the
deep lateral wall maximizes the decompressive
effect [19]. The addition of fat removal increases
the safety of the procedure and the magnitude
of proptosis reduction [20, 21].
There is extensive literature describing the
various techniques for orbital decompression
but there is no consensus on the most efficient
and safe intervention [8, 12, 13, 20, 22–27]. The
inclusion of different indications, in different
stages of natural history and the lack of uniform
method for motility evaluation have skewed the
comparative results [28, 29].
The present study summarizes the current
evidence-based data on the efficacy of surgical
orbital decompression for TED and possible
information on complications andquality of life.
METHODS
The foundation of this review is a previously
conducted systematic review and meta-analysis
for the Cochrane Collaboration [22]. We did
not require the approval of our institutional
review board as the analysis in this article
evaluates previously conducted studies and
does not involve any new studies of human or
animal subjects performed by any of the
authors. Reporting of the methodology and
results of the systematic review was guided by
the PRISMA guidelines [30].
Inclusion Criteria
The review includes unrestricted randomized
controlled trials (RCTs) resulting from a detailed
search strategy. In addition, review or large case
series non-randomized studies will be analyzed.
Outcome Measures
Primary outcome is considered the success rate
compared to the failures as defined in each
study by means of composite scores [31, 32] or
ordinal score [33]. Outcomes are evaluated from
1 to 6 months following surgery. Secondary
outcomes include the post-decompression
corrective procedures for pre-existing
conditions like motility and eyelid alterations,
disease severity measured by the NOSPECS score
[34], or the total eye score [35], and
exophthalmometry measurements of disease
activity evaluated with the clinical activity
score [36].
Adverse outcomes are considered
surgery-induced strabismus or visual loss, other
possible complications, and discontinuations of
treatment. Where available, quality of life data
measured with the Graves’ ophthalmopathy
quality of life tool (GO-QOL), a disease-specific
validated questionnaire will be included [37].
Literature Search Methods
We searched CENTRAL which contains the
Cochrane Eyes and Vision Group Trials
Register (2015, Issue 1), part of The Cochrane
Library (http://www.thecochranelibrary.com),
MEDLINE (January 1950 to February 2015),
EMBASE (January 1980 to February 2015),
PubMed (January 1948 to February 2015), the
metaRegister of Controlled Trials (mRCT)
(http://www.controlled-trials.com), andClinical
Trials.gov (http://www.clinicaltrials.gov), with
no language or date restrictions. The most
updated electronic database search was on 2
March 2015, based on the strategy suggested by
Glanville et al. [38] (see ‘‘Appendix’’).
The reference lists of the included trials were
assessed with the Science Citation Index for
possible publications that cited the included
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trials in this review. We contacted investigators
and experts in the field for additional trials.
Data Collection and Analysis
Search results screened for appropriate studies.
We reviewed the full text of studies with
relevance to the review and assessed for
methodological quality those that met the
selection criteria. Disagreements were resolved
by discussion. We extracted data onto a
standardized data extraction form, reconciled
differences and resolved disagreements before
contacting investigators for further information
where data was unclear.
Risk of Bias Assessment
Included trials were assessed for risk of bias
following Higgins et al.’s methodology [39].
Possible areas for risk of bias were selection
process and sequence generation, incomplete
outcome data, and selective outcome reporting,
classifying each trial as low, unclear, or high risk
of bias.
For measures of treatment effect we followed
the methodology for Systematic Reviews of
Interventions suggested by Deeks et al. [40].
We used the odds ratio for the primary outcome
measure (success or failure of treatment) as
reported data was dichotomous. A possible unit
of analysis issue is the inclusion of both eyes
from participants with no provision for this in
the analysis. When relevant data from the
included studies was unclear or incomplete,
we contacted the investigators for the missing
information.
Variety of study designs and methodological
differences would normally produce some
degree of heterogeneity. Should more trials be
included in future updates, we will assess
statistical heterogeneity and consistency
between using the I2 statistic and funnel plot
analysis for publication bias. The two included
studies revealed substantial clinical
heterogeneity and meta-analysis of the results
was not appropriate; we therefore present a
descriptive summary of results supplemented
with clinically important data from excluded
studies.
Compliance with Ethics
The analysis in this article is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
RESULTS
Results of Search Strategy
The updated electronic searches revealed 1195
titles, 160 more than the published Cochrane
review [22]. After removing duplicated and
irrelevant results, we scanned 1058 records
and discarded 914 titles because they were
outside the scope of our review. From the
remaining 144 references, there were no
additional RCTs identified from the ones that
were included in our systematic review (Fig. 1).
Clinically meaningful information from the
excluded 142 studies supplemented the results
in a descriptive outline. Personal
communication with the European Group for
Graves Ophthalmopathy (EUGOGO) revealed a
protocol for RCT comparing three surgical
techniques of orbital decompression but this is
in the early stages with no study registration
yet.
Included Studies
Only two RCTs were eligible for inclusion in the
review [41, 42]. As a result of methodological
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and clinical heterogeneity no meta-analysis was
performed and we present the results
individually.
Pliego-Maldonado et al. [41] compared the
Walsh-Ogura transantral approach with
Kennedy’s endoscopic endonasal technique for
orbital decompression for TED (Table 1). Both
methods produced similar reduction of
exophthalmos. There was no data on
composite outcome, clinical activity, or total
eye scores. Similarly, no secondary outcomes
were reported. The Walsh-Ogura technique was
associated with higher rates of complication,
mainly diplopia and infraorbital nerve damage
(Table 2).
In the second study, Wakelkamp et al. [42]
compared the surgical bony wall removal via a
coronal approach with the intravenous
administration of methylprednisolone for
DON (Table 3). There was an improvement in
visual acuity, total eye and clinical activity
scores at 52 weeks post treatment). Success was
reported in 56% of the steroid group and 17% of
the surgical group in cases of DON (Table 4).
Additional interventions were recorded in a
mean follow-up of 64 months for the surgery
group where five out of six participants needed
immunosuppression and three out of six
needed squint surgery, followed by eyelid
surgery in five out of six. Similarly, within
78 months in the steroids group, four out of
nine had a decompression, and later five out of
nine participants needed squint surgery,
followed by eyelid surgery in four out of nine.
From the total number of 15 randomized
participants, only two did not require
rehabilitative surgery and they were both in
the steroids group. Five participants in the same
group did not undergo surgical decompression
(Table 5). Treatment side effects were more
frequent in the steroids group and included
weight gain and a cushingoid appearance in 12
out of 15 patients, hypertension and reversible
hyperglycemia in one case, and visual
deterioration in one eye due to retinal vein
occlusion. Side effects of surgery were transient
infraorbital hypoesthesia in four out of 14
participants, and strabismus in one participant.
Risk of Bias in Included Studies
Sequence generation was unclear in
Pliego-Maldonado et al.’s study [41] because
their randomization method was not stated.
Wakelkamp et al. [42] randomized patients
following pretreatment stratification using
Fig. 1 Flow diagram of the study process. Search and
identiﬁcation of studies for inclusion in the review
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envelopes in two blocks of four per block.
Potential risks of bias for both trials are the
lack of allocation concealment of intervention
assignment and no evidence of masking. Both
studies adequately addressed incomplete
outcome data and clearly reported the main
outcome measures.
The excluded studies identified by our search
strategy did not provide credible evidence for
decompressive surgery. Their description of
Table 1 Characteristics of included study by Pliego-Maldonado
Methods Randomized controlled trial. More than one eye per participant was included
Participants Patients with Graves’ disease exophthalmos ([22 mm) who were euthyroid for at least 6 months after
treatment
26 eyes in 17 participants were decompressed using the Walsh-Ogura technique (group 1)
18 eyes of 18 participants were decompressed using the Kennedy’s surgical approach (group 2)
Gender ratio 11 male, 24 female
Group 1 mean age 42.8 years SD (14.6); group 2 mean age 36.7 years SD (11.4)
Interventions Walsh-Ogura technique was compared with the Kennedy’s surgical approach
Outcomes Exophthalmos measurements, diplopia infraorbital nerve lesion
Notes Paper published in Spanish
Risk of bias
Bias Authors’ judgment Support for judgment
Random sequence generation (selection bias) Unclear risk No details are given regarding sequence
generation
Allocation concealment (selection bias) High risk No evidence of concealment
Blinding (performance bias and detection bias)
All outcomes
High risk It is not stated that the physicians or
participants were masked to the
intervention used
Incomplete outcome data (attrition bias)
All outcomes
Low risk Exophthalmometry measures and
complications were presented in tables
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Table 2 Comparison of the adverse events related to two surgical methods for orbital decompression
Study Outcome Walsh-Ogura Kennedy
Pliego-Maldonado Diplopia 22/26 eyes 13/18 eyes
Infection 3/26 eyes 0/18 eyes
Intraorbital nerve lesion 13/26 eyes 0/18 eyes
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surgical technique and outcome data varies
significantly; there is identifiable bias in the
surgical preference and considerable
underreporting of potential complications
from a larger cohort of patients. It is therefore
inconclusive to present their findings in detail
Table 4 Relative successes of surgical orbital decompression versus medical treatment
Studyor Surgery Medical OddsRatio OddsRatio
subgroup
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wakelkamp2005 1/6 5/9 0.16 [ 0.01, 1.98 ]
0.01 0.1 1 10 100
Favorsmedical treatment Favors surgery
Table 3 Characteristics of included study by Wakelkamp
Methods Randomized controlled trial. If participants did not respond they were switched to the other treatment arm;
however the last observation prior to the switch was used in the analysis
Participants Participants with very active Graves’ ophthalmology and optic neuropathy aged between 18 and 80 years.
Participants already treated with corticosteroids or any other treatment such as surgery or radiotherapy
were excluded. Patients were included if they had at least ﬁve or more of the ﬁrst seven items used to
determine clinical activity score and at least one of the last three. Pinhole visual acuity of\0.63 due to
optic neuropathy and not due to corneal problems alone or other pre-existing eye disease
Interventions Surgical decompression—a three-wall coronal decompression versus methylprednisolone iv pulses 1 g daily
for three consecutive days, repeated after 1 week, followed from day 15 onwards by oral prednisolone for
4 months in a tapering dose
Outcomes Primary outcome was change in visual acuity. Clinical activity score was reported. Response was evaluated at
26 weeks after therapy started or earlier if initial therapy failed
Risk of bias
Bias Authors’ judgment Support for judgment
Random sequence generation (selection bias) Low risk Randomization was performed after stratiﬁcation
for pre-treatment and in two blocks of four
per block using envelopes
Allocation concealment (selection bias) Unclear risk It is not stated how the envelopes were assigned
to participants and opened
Blinding (performance bias and detection bias)
All outcomes
High risk The physicians or participants were not masked
to the intervention
Incomplete outcome data (attrition bias)
All outcomes
Low risk There was no incomplete data
Selective reporting (reporting bias) Low risk No evidence of selective reporting
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and we only summarize their results in terms of
technique effectiveness, indications, and
complication rate.
A large multicenter study evaluated 139
euthyroid patients (248 orbits) with inactive
GO who underwent decompressive surgery for
disfiguring proptosis [28]. The procedure was
performed by an ophthalmologist in nine of the
11 centers with the assistance of a maxillofacial
surgeon in two, whereas endonasal
decompression was performed by an ear, nose,
and throat surgeon (ENT) in the remaining two.
Three-wall decompression resulted in higher
reduction of proptosis compared to the
two-wall procedure despite the fact that the
former was reserved for patients with significant
preoperative proptosis. A linear regression
analysis showed that the difference in surgical
outcome was not due to the preoperative
difference in exophthalmos alone. A subgroup
analysis of cases with similar preoperative
exophthalmos documented that the mean
proptosis reduction after three-wall
decompression was 5.8 (SD 1.7) mm,
significantly more than 4.6 (SD 1.0) mm after
two-wall decompression.
The addition of fat removal augmented the
effectiveness of the procedure but this only
reached statistical significance in cases of
three-wall decompression. Further analysis
showed that the three-wall coronal approach
produced significantly higher proptosis
reduction compared to three-wall swinging
eyelid (±transcaruncular), three-wall translid,
and endoscopic decompression, respectively.
Similarly, as regards the two-wall procedures,
the endoscopic approach resulted in
significantly lower proptosis reduction
compared with swinging eyelid and
transconjunctival or transcaruncular
approaches (Table 6).
The three-wall procedures were associated
with more complications than two-wall
decompressions and specifically in the coronal
approach; complications were more frequent
and severe. Adverse events included maxillary
sinus obstruction, hypoglobus, and persistent
eyelid swelling with scar dissatisfaction in the
swinging eyelid three-wall procedures.
Temporal bossing, paralysis of frontalis
muscle, and cerebrospinal fluid (CSF) leak
occurred after coronal approach, whereas the
last of these also occurred with the endoscopic
approach.
Consecutive diplopia developed in 35.7% of
coronal approaches, 11% of the
transconjunctival/transcaruncular two-wall
decompression, and in 100% of the
endoscopic group. These findings regarding
effectiveness, complications, and motility
disturbance are comparable to the published
literature of uncontrolled trials, retrospective
studies, and case reports. Published data
suggests that three-wall decompression
Table 5 Adverse events of surgical orbital decompression versus medical treatment
Study Squint surgery Eye lid surgery Lack of response pinhole £0.63
Signs of optic neuropathy at 26 weeks
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produces superior reduction proptosis than all
the other methods but with high risk of
potential complications, mainly induced
diplopia, hypoglobus, and infraorbital nerve
hypoesthesia [22, 43–48]. Less invasive
procedures like the balanced two-wall
decompression with or without endoscopic
assistance for removal of the medial wall are
gaining popularity because their satisfactory
outcome relates to fewer complications and de
novo strabismus [49–56].
Removal of the deep lateral wall may
sufficiently decompress the orbital content
and is becoming the procedure of choice
either alone or in combination with other
techniques. The published degree of proptosis
reduction varies from 2.3 mm in the early
reports [19] to a range of 3–7 mm with
technique advancements [25, 57]. Total
removal of the lateral orbital rim offers
maximum globe retrodisplacement of up to
9 mm and augments the efficacy of the
procedure [58, 59]. Removal of the deep lateral
wall is the safest decompressive procedure,
associated with minimal if any complications.
It has no significant effect on horizontal and
vertical deviations with a low rate (2.6%) of new
onset diplopia, whereas in some cases
preoperative diplopia was corrected after
surgery [19, 60, 61].
First-line treatment for DON consists of high
dose intravenous steroids followed by urgent
orbital decompression with removal of the
medial wall offering the most effective relief of
optic nerve compression [42, 62–67]. The
transcaruncular approach to medial wall
allows easy and safe access to the orbital apex
for removal of the ethmoidal bone and
maximum relief of optic nerve compression.
This technique is only comparable to the
endoscopic approach to medial wall and
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decompression methods for the management of
DON [65, 68–74].
Olivary first introduced removal of
periocular fat for orbital decompression in
1991. The average amount of fat removed was
6.0 cc and resulted in a 5.9-mm reduction of
proptosis which is comparable to the published
results for removal of bony wall [75–77]. Other
studies report contradictory results with more
fat excision required per millimeter of proptosis
reduction (mean 7.3 ml of fat for a 4.7-mm
reduction) with the technique, producing
significantly less reduction of exophthalmos
[78–81]. Intraconal fat removal, alone or in
combination with other techniques, may
effectively alleviate optic nerve compression.
The literature reports suggest it is comparable to
bony decompression for the management of
DON in selected cases [27, 72, 81, 82].
DISCUSSION
We did not find RCTs to support robust
evidence for recommending a specific method
for orbital decompression, as a result of the
significant diversity of design, methodology,
and outcome measures.
Pliego-Maldonado et al. [41] suggest that the
Walsh-Ogura technique and Kennedy’s
transnasal approach are equally efficient in
reducing exophthalmos but the latter is safer
and associated with fewer adverse outcomes.
Wakelkamp et al. [42] conclude that
intravenous steroids are more efficient than
primary surgical decompression for managing
DON, requiring less corrective interventions in
the long-term. The benefit of intravenous
steroids on visual rehabilitation supersedes the
higher incidence of transient side effects. Before
more evidence becomes available, we cannot
make documented recommendations for
clinical practice.
Current practice may vary geographically
and strongly relates to the preference of each
medical specialty [13]. From the two procedures
compared by Pliego-Maldonado et al. [41], the
Walsh-Ogura was related to a higher incidence
of complications and it is rarely used in current
practice. Kennedy’s transnasal approach is the
preference of ENT surgeons for removal of the
medial wall and is often combined with other
techniques for maximizing outcome.
Wakelkamp et al. [42] have documented the
superiority of intravenous steroids for the
management of DON but this trial was small
and the observed difference was not statistically
significant.
The body of evidence from the included
studies does not allow for a documented
conclusion regarding the objectives of this
review. The study by Pliego-Maldonado et al.
[41] is lacking information on allocation of
treatment and masking and has a comparatively
short follow-up period of 4 months. In contrast,
Wakelkamp et al. [42] offer high
methodological quality, but include a small
number of patients (six and nine patients in
each treatment arm) so that the observed
difference between groups can be attributed to
chance. The limited number of studies and the
significant methodological diversity do not
allow for a meta-analysis of the results. The
available evidence relates to the review question
but it is insufficient to address all the review
objectives.
Potential risk of other sources of bias was
unclear in both studies. This was due to the
small number of patients in the Wakelkamp
et al. study [42] and poor methodological
quality and short follow-up in the
Pliego-Maldonado et al. study [41]. Bias may
distort systematic reviews and meta-analyses
and encourages the use of questionable
treatments [83]. This is not an issue for this
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review because of lack of adequate evidence to
formulate recommendations for practice.
There are an abundance of published data on
surgical orbital decompression for TED, mainly
retrospective, cohort, and case series studies.
These studies do not contribute to the
development of documented guidelines for the
efficacy and safety of a specific procedure except
in cases of DON because they relate to different
indications for decompression, different stages
of TED with different outcome measures.
A descriptive summary of the available
uncontrolled studies may suggest that
three-wall decompression is the most effective
procedure in reducing exophthalmos but is
associated with a higher rate of complications,
mainly hypoglobus and induced diplopia [28,
44, 47, 84]. Surgical preference is shifting
towards safer techniques with similar effect
but fewer complications like the balance
two-wall decompression or removal of the
deep lateral wall [19, 25, 28, 60]. Removal of
the medial wall is indicated for relief of optic
nerve compression in cases of DON and is better
performed via transcaruncular or endoscopic
approach [72, 73, 85]. Removal of periocular fat
may alleviate the intraorbital pressure and is
even effective in cases of DON [27, 72, 79, 80,
82]. In clinical practice, the techniques for
removal of medial and lateral wall are often
used in combination with or without
endoscopic assistance and their result is
augmented by additional fat removal [21, 72,
86–88].
Recent improvements in surgical technique
have incorporated advanced technology for
optimizing results and reducing
complications. The application of stereotactic
navigation systems offers accurate anatomical
guidance in the surgical field and improves
safety but with higher cost [89–91]. Changes in
instrumentation for bone removal like
ultrasonic versus high speed burring or
microdebrider facilitate accurate tissue
removal with less adverse events [92, 93]. A
recent study evaluated a novel method for
bone removal with the use of a piezosurgical
device. It allows selective bone removal and
therefore enhances surgical precision and, in
theory, reduces the adverse events related to
excessive trauma. Nevertheless, this technique
offers no improvement in outcome or




The first included RCT [41] compared two
surgical approaches for orbital decompression
in patients with disfiguring TED. The
treatments produced equal reduction of
exophthalmos, but Kennedy’s transnasal
approach exhibited less surgical complications.
These techniques are not routinely used by
ophthalmologists and have been replaced by
safer and more efficient approaches. Kennedy’s
endoscopic approach is still used by ENT and
maxillofacial surgeons for the removal of the
medial wall and is usually combined with other
techniques for optimum decompression. The
second included trial [42] compared three-wall
bone removal versus intravenous steroid
medical decompression for DON.
Several non-randomized studies suggest that
three-wall decompression via coronal or
swinging eyelid transconjunctival approach
offers the best reduction of proptosis but is
associated with higher rates of complication
[13, 16, 23, 28, 52, 95–97]. Balanced
decompression by removal of medial and
lateral wall with or without fat removal may
be more preferred for balancing optimum
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effectiveness with relative safety and fewer
complications [22, 28, 62, 86, 98]. Recently,
the deep lateral wall approach is gaining
acceptance as it offers satisfactory
decompression with minimum complications
and can be combined with other techniques,
mainly transcaruncle medial wall
decompression with or without fat removal
[16, 19, 25, 60, 61, 93]. There are several
reports that orbital fat removal is safer than
and equally efficient as bony wall
decompression [75–77, 99]. It may also relieve
intraconal pressure on the optic nerve and
improve visual function in cases with DON
[27, 82, 100]. When combined with other
techniques of bone removal it increases the
efficacy of decompression and minimizes the
rate of surgical complications [20, 21, 86]. These
studies are non-randomized, mainly
retrospective case series and non-comparative.
It is therefore difficult to draw evidence-based
conclusions regarding which method offers
optimum decompression and has a lower
complication rate. Similarly, we could not find
evidence to compare the quality of life or the
cost of any surgical technique in this condition.
Recent supportive technological advances like
stereotactic navigation, ultrasonic or
piezosurgical bone removal have not yet
proven to yield significant improvements in
outcome or safety to justify the additional cost
[94].
Implications for Research
There is a clear unmet need for well-structured,
prospective randomized clinical trials to
compare surgical methods for orbital
decompression in TED. It is imperative to
produce credible scientific evidence by
evaluating and comparing the most effective
currently used procedures of three-wall,
balanced two-wall, deep lateral wall, and
transcaruncle medial wall decompression with
or without orbital fat removal.
Comparison of any of these or combination
of approaches with another technique would
also be valuable for formulating guidelines for
future clinical practice. In cases of compressive
optic neuropathy, comparison of surgical
decompression with any form of
anti-inflammatory and immunosuppressive
treatment (medical decompression) would be
necessary, as it has been documented that
medical decompression is the best first-line
treatment for DON [26, 42]. These studies
must address primarily the following
outcome measures: reduction of
exophthalmos, disease severity (NOSPECS
score), disease activity or composite outcome
score, complication rate, quality of life, and
cost of the intervention. Conducting a
prospective RCT for a surgical intervention
applicable only to a small percentage of
patients suffering from TED which overall is
considered a rare disease is a challenging but
necessary undertaking and would require a
multicenter collaboration of experts in the
field such as EUGOGO in Europe and the
International Thyroid Eye Disease Society
(ITEDS) in the USA.
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APPENDIX
Search strategy for MEDLINE
1. randomized controlled trial.pt.





7. groups.ab,ti. 8. or/1–7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp graves disease/
14. graves ophthalmopathy/
15. (grave$ adj3 ophthalm$).tw.
16. (grave$ adj3 orbitopath$).tw.
17. ((ophthalm$ or eye$) adj3 thyroid$).tw.
18. (basedow$ adj3 disease$).tw.
19. exp exophthalmos/
20. (exophthalm$ or proptos$).tw.
21. exp optic nerve diseases/
22. ((disease$ or neuropath$) adj2 optic
nerve$).tw.
23. (TAO or TED).tw. 24. or/13–23
25. exp ophthalmological surgical procedures/
26. exp decompression, surgical/
27. decompress$.tw. 28. or/25–27
29. 24 and 28
30. 12 and 29
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